Suchergebnisse - "Morimoto, Takeshi"

PubPharm (30)

1

Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease　- An Observation From the REAL-CAD Study

enthalten in: Circulation journal : official journal of the Japanese Circulation Society | 2023

von Toyota, T. | Morimoto, T. | Iimuro, S. | +20

2

Sex Differences in Clinical Outcomes After Percutaneous Coronary Intervention

enthalten in: Circulation journal : official journal of the Japanese Circulation Society | 2023

von Takeji, Y. | Morimoto, T. | Shiomi, H. | +30

3

Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study

enthalten in: Biomedicine hub | 2022

von Miwa, Y. | Mutoh, A. | Morimoto, T. | +13

4

Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan　- From the CREDO-Kyoto Registry Cohort-2 and Cohort-3

enthalten in: Circulation journal : official journal of the Japanese Circulation Society | 2022

von Natsuaki, M. | Morimoto, T. | Shiomi, H. | +40

CommentIn: Circ J. 2022 Apr 25;86(5):760-762. - PMID 34670877

5

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention : a genetic substudy from the STOPDAPT-2

enthalten in: Cardiovascular intervention and therapeutics | 2021

von Watanabe, H. | Morimoto, T. | Ogita, M. | +23

ErratumIn: Cardiovasc Interv Ther. 2021 Feb 12;:. - PMID 33580476

6

Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention　- From the CREDO-Kyoto Registry Cohort-3

enthalten in: Circulation journal : official journal of the Japanese Circulation Society | 2021

von Natsuaki, M. | Morimoto, T. | Shiomi, H. | +33

CommentIn: Circ J. 2021 May 25;85(6):782-784. - PMID 33504744

7

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2

enthalten in: Cardiovascular intervention and therapeutics | 2020

von Watanabe, H. | Morimoto, T. | Ogita, M. | +22

8

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2

enthalten in: Cardiovascular intervention and therapeutics | 2020

von Watanabe, H. | Morimoto, T. | Ogita, M. | +22

9

Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2

enthalten in: Cardiovascular intervention and therapeutics | 2020

von Watanabe, H. | Morimoto, T. | Ogita, M. | +22

10

Effects of Body Weight on Bleeding and Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention　- From the CREDO-Kyoto Registry Cohort-2

enthalten in: Circulation journal : official journal of the Japanese Circulation Society | 2020

von Yamamoto, K. | Natsuaki, M. | Yoshikawa, Y. | +19